The companies on the Global 500 employ 70.2 million people, and their revenue represents more than one-third of the world’s GDP.

Fortune Global 500

With a combined revenue of $21 trillion and $2.1 trillion in profits, the 2026 Fortune 500 is the definitive list of America's largest companies.

Fortune 500

The 300 companies on this year’s list brought in over $12.5 trillion in revenue for the latest 12 months, with the median revenue figure at $24 billion.

America's Most Innovative Companies

AI is a major force shaping this year’s list—but it’s far from the only story.

World's Most Admired Companies

Companies that foster an environment that supports professional growth are more likely to thrive and successfully adopt digital innovation. Here are the 100 best places to work in Europe—and how they stay that way.

Johnson &amp; Johnson ranks 52 on this year’s Fortune 100 Best Companies to Work For – Europe list.

Fortune 100 Best Companies To Work For – Europe

This ranking evaluates how Fortune 500 companies are deploying AI, and how technology leaders value those investments relative to industry peers.

Fortune AIQ 50

The corporations on our annual list of the world's 500 largest companies combined to generate $41.7 trillion in revenue over the past year.

Almost $20 trillion in revenue—and a record-breaking $1.87 trillion in profits. Introducing the 2025 Fortune 500, the definitive list of the biggest companies in America.

The 300 companies on this year’s list brought in over $12.6 trillion in revenue for the latest 12 months, with the median revenue figure at $22 billion.

Leaders in all industries rely more than ever on Big Tech—and appreciate the giants that deliver, at scale, without drama.

The corporations on our annual list posted aggregate revenues of $41 trillion for the second year in a row.

Industries included in the sector are insurance and managed care, medical products and facilities, pharmacy services, and pharmaceutical companies.

Fortune Sector Leaders: Health Care

The Fortune 500, in its 70th year in 2024, ranks the biggest U.S. companies by revenue.

The 200 companies on this list are transforming industries from the inside out.

The 26th edition of the list shows how much esteem Big Tech giants command among other business leaders.

WMA-2024-Johnson-and-Johnson

The 25th Fortune World’s Most Admired Companies list suggests that tech giants’ peers respect them as much as ever.

WMAC 2023-Johnson and Johnson

The corporations on our annual list of the world’s largest companies delivered a record $41 trillion in aggregate revenues.

The 300 companies on this list are transforming industries from the inside out.

The Fortune 500, in its 69th year in 2023, ranks the biggest U.S. companies by revenue.

F500-2023-040-Johnson-and-Johnson

The health care company is best known for household items like baby shampoo and Tylenol, but pharmaceuticals and medical technology are its big revenue drivers, bringing in $52.5 billion and $27.4 billion respectively, compared to $14.9 billion in the consumer health segment. 
<ul> 
 	<li>Revenue inched up 1.2% to $94.9 billion in 2022, but profits fell 14.1% to $17.9 billion.</li> 
 	<li>The U.S. government phased out Johnson &amp; Johnson’s one-shot COVID vaccine, hurting the company’s pharmaceutical division.</li> 
 	<li>In April 2023, the company settled a decade-long legal dispute in which consumers accused J&amp;J’s iconic baby powder of causing cancer. The company agreed to pay $8.9 billion to tens of thousands of plaintiffs but has not admitted wrongdoing. Before the settlement is final, a court must accept a controversial bankruptcy filing by a subsidiary that Johnson &amp; Johnson created to shield its corporate assets from litigation. A court rejected an earlier bankruptcy filing aimed at reaching a settlement, which allowed thousands of related cases against J&amp;J to go ahead.</li> 
</ul>

Just as it dominates our economy, Big Tech now dominates Fortune’s annual ranking of corporate reputation.

WMAC-2022-17-Johnson and Johnson

Aggregate sales hit $37.8 trillion last year—an increase of 19%, the highest annual growth rate in the list’s history.

This year’s Fortune 500 marks the 68th running of the list.

F500 2022-Johnson and Johnson

J&amp;J is home to globally known household products such as Tylenol pain medication and Aveeno body lotion. But over the past year, its health care and pharmaceutical businesses made the most news. The company began distributing its Janssen single-dose COVID-19 vaccine in March 2021. Manufacturing problems and the vaccine’s lower efficacy compared with products from Pfizer-BioNTech and Moderna hindered its adoption, but as of May 2022 about 19 million doses had been administered in the U.S., and millions more internationally. In July 2021, J&amp;J agreed to pay up to $5 billion as part of a nationwide settlement agreement to fund state and local efforts to address the opioid crisis. (The company admitted no wrongdoing related to marketing of its pain medications.) And in November 2021 the company announced that it would essentially become a pharma pure play; by late 2023, J&amp;J will spin off its consumer products businesses as a separate company.

After a year in which humanity leaned more heavily than ever on tech giants, see which companies topped Fortune's ranking of corporate reputation.

WMAC 2021-15-Johnson & Johnson

Total revenue for the world’s biggest companies fell 4.8% to $31.7 trillion this year—the first decline in half a decade.

G500-2021-094-Johnson & Johnson

The 135-year-old global health care conglomerate sells everything from Band-Aids and artificial hips to surgical robots, cancer drugs, and one of America’s first three authorized COVID vaccines. The pandemic affected many of those businesses, and J&amp;J’s sales overall were relatively flat last year—notching up 0.6%. While the company’s pharmaceutical division performed well, results were mixed for the consumer segment: Sales of over-the-counter products like Tylenol surged, while baby care and women’s health revenues plummeted. Likewise, the company’s medical devices business recorded a sales decline of 11.6%, largely owing to people delaying procedures during the pandemic.

This year’s Fortune 500 marks the 67th running of the list.

F500-2021-36-Johnson & Johnson

For an astounding 13th straight year, Apple claims the top spot in Fortune’s annual ranking of corporate reputation, based on a survey of almost 3,800 executives, directors, and analysts.

This year's Fortune Global 500 generated $33.3 trillion in revenues and $2.1 trillion in profits.

G500-2020-104-JJ

The sprawling 134-year-old health conglomerate eked out 0.6% sales growth in 2019 thanks to the strong performance of its pharmaceutical business, and particularly its immunology and oncology drugs. J&amp;J’s consumer business—with a portfolio that includes Neutrogena, Tylenol, and Listerine—was boosted by the acquisition of Zarbee’s, a purveyor of naturally based over-the-counter remedies. The company continued its push into the robotic surgery market in an effort to revive its struggling medical device business. J&amp;J is also mired in litigation surrounding its opioid and baby powder products. (In May, it announced it would stop selling talc-based baby powder.) While COVID-19 has dinged sales of some of its products—like contact lenses and artificial knees and hips—the company is one of the frontrunners in the race for a vaccine; J&amp;J has said it hopes to begin late-stage human trials by the end of September.

This year's Fortune 500 marks the 66th running of the list.

F500-2020-035-Johnson and Johnson

The sprawling 134-year-old health conglomerate eked out 0.6% sales growth in 2019 thanks to the strong performance of its pharmaceutical business, and particularly its immunology and oncology drugs. J&amp;J’s consumer business—with a portfolio that includes Neutrogena, Tylenol, and Listerine—was boosted by the acquisition of Zarbee’s, a purveyor of naturally based over-the-counter remedies. The company continued its push into the robotic surgery market in an effort to revive its struggling medical device business. J&amp;J is also mired in litigation surrounding its opioid and baby powder products. No surprise, the company has been impacted by COVID-19 in various ways; while its pharma division is racing to develop a vaccine, sales of products like artificial knees and hips are down due to the cancellation of elective surgeries during the pandemic.

Here are the World's Most Admired Companies for 2019 as ranked in their industries. See who made the list.

This year's Fortune Global 500 generated $27.7 trillion in revenues and $1.5 trillion in profits.

This year's Fortune 500 marks the 65th running of the list.

Here are the World's Most Admired Companies for 2018 as ranked in their industries. See who made the list.

This year's Fortune 500 marks the 64th running of the list.

Here’s our look at 57 companies that do well by doing good.

Change the World

Here are the World's Most Admired Companies for 2017 as ranked in their industries. See who made the list.

This year's Fortune 500 marks the 63rd running of the list.

Here’s our look at 50 companies that do well by doing good.

Here are the World's Most Admired Companies for 2016 as ranked in their industries. See who made the list.

This year's Fortune Global 500 generated $27.6 trillion in revenues and $1.5 trillion in profits.

This year's Fortune 500 marks the 62nd running of the list.

Business insiders have spoken: Asked which companies they most admire, more than 4,100 executives, directors, and analysts chose these top 50 All-Stars.

The world's 500 largest companies generated $31.2 trillion in revenues and $1.7 trillion in profits in 2014. Together, this year's Fortune Global 500 employ 65 million people worldwide and are represented by 36 countries.

This year's Fortune 500 marks the 61st running of the list. Wal-Mart claims the top spot again. See who made the list.

Global business is back. After limping through a worldwide financial crisis and economic slowdown, the 500 largest companies ranked by revenues shattered all sorts of performance records in 2013: They racked up combined revenues of $31.1 trillion, up 2.5% from 2012, and profits soared 27% to nearly $2 trillion. China’s 95 companies (up from 89 last year) posted $5.8 trillion in revenues. The U.S. has four fewer companies on the list than last year but remains (for now) the country leader, with 128 corporations on the list—including No. 1 Wal-Mart Stores—reporting $8.6 trillion in revenues. 

Wal-Mart stayed on top as its sales crept closer to half-a-trillion dollars. Apple moved into the top five. And UnitedHealth Group continued its steady climb. 

Best Companies To Work For Europe

Sector

CEO/Top executive

Group headquarters

HQ location

GPTW national list

Woman CEO

Number of Years on List

Industry

Current All-Star Rank

Previous All-Star Rank

Industry Rank

Previous Industry Rank

Overall Score

Innovation

People Management

Use of Corporate Assets

Social Responsibility

Quality of Management

Financial Soundness

Long-Term Investment Value

Quality of Products/Services

Global Competitiveness

Strongest Dimension

Years on list

Previous rank

State

Key Financials (last Fiscal Year)

Revenues ($M)

Profits ($M)

Assets ($M)

Total Stockholder Equity ($M)

Profit Ratios

Profit as % of Revenues

Profits as % of Assets

Profits as % of Stockholder Equity

Earnings Per Share (last Fiscal Year)

Earnings Per Share ($)

EPS % Change (from prior fiscal year)

EPS % Change (5 year annual rate)

EPS % Change (10 year annual rate)

Total Return

Total Return to Investors (last year)

Total Return to Investors (5 year, annualized)

Total Return to Investors (10 year, annualized)

Johnson &amp; Johnson, founded in 1886, is among the world’s largest and most influential health care companies. It is involved in the research, development, manufacture, and distribution of innovative medicines and medical technologies. The company’s innovative medicine business operates in areas including oncology, immunology, neuroscience, and cardiopulmonary treatment. In medtech, the company is focused on developing and delivering cardiovascular, orthopedics, surgery, and vision solutions.

Q2 2026

Q1 2026

Q4 2025

Q3 2025

Q2 2025

Q1 2025

Q4 2024

Johnson & Johnson (JNJ): Company Profile, Stock Price, News, Rankings

legacy

Johnson & Johnson

johnson & johnson

Good morning, and welcome to Johnson and Johnson's First Quarter twenty twenty five Earnings Conference Call. All participants will be in a listen only mode until the question and answer session of the conference. This call is being recorded. If anyone has any objections, you may disconnect at this time. If you experience technical difficulties during the conference, you may press 0 to reach the operator.

I would now like to turn the conference call over to Johnson and Johnson. You may begin.

Hello, everyone. This is Jessica Moore, Vice President of Investor Relations for Johnson and Johnson. Welcome to our company's review of business results for the first quarter of twenty twenty five and our updated financial outlook. A few logistics before we get into the details. As a reminder, you can find additional materials, including today's presentation and associated schedules on the Investor Relations section of the Johnson and Johnson website at investor.jnj.com.

Please note that this presentation contains forward looking statements regarding, among other things, the company's future operating and financial performance, market position and business strategy. You are cautioned not to rely on these forward looking statements, which are based on the current expectations of future events using the information available as of the date of this recording and are subject to certain risks and uncertainties that may cause the company's actual results to differ materially from those projected. A description of these risks, uncertainties and other factors can be found in our SEC filings, including our 2024 Form 10 ks, which is available at investor.jnj.com and on the SEC's website. Additionally, several of the products and compounds discussed today are being developed in collaboration with strategic partners or licensed from other companies. This slide acknowledges those relationships.

Moving to today's agenda. Joaquin Duato, our Chairman and CEO, will open with a few comments on our performance and key catalysts for the company. John Reed, our Executive Vice President, Innovative Medicine R and D, will highlight recent data from select assets. I will then review the first quarter sales and P and L results. Joe Walk, our CFO, will then close by sharing an overview of our cash position, capital allocation priorities and guidance for 2025.

Jennifer Taubert, Executive Vice President, Worldwide Chairman, Innovative Medicine and Tim Schmid, Executive Vice President, Worldwide Chairman, MedTech, will be joining us for Q and A. To ensure we provide enough time to address your questions, we anticipate the webcast will last slightly over sixty minutes. With that, I will now turn the call over to Joaquin.

Thank you, Jess, and hello, everyone. In the first quarter, we delivered strong operational sales growth of 4.2% across our business. Our Q1 performance reinforces my confidence in our 2025 guidance and reflects the strength of Johnson and Johnson's uniquely diversified business with year over year sales increases in both our innovative medicine and med tech sectors. No other healthcare company has delivered growth through the first year of losing exclusivity for a multibillion dollar product. In our case, Stellara.

And yet, that is exactly what we are doing. Our resiliency is a testament to what makes us unique. We are not just a pharmaceutical company or a med tech company. We are a healthcare company, innovating across the full spectrum of disease. Our consistent strong performance is a testament to our capabilities across commercial, R and D and supply chain.

It is also a reflection of our strength in execution, which you can see in our quarterly results. We have described 2025 as a catalyst year. It is a year that will set us up for accelerated growth through the second half of the decade and beyond. In Q1, the power of our portfolio and pipeline was on full display. In Innovative Medicine, we delivered 4.2% operational sales growth despite an approximate eight ten basis points headwind from Stelara with 11 key brands growing double digits.

With our third consecutive quarter of sales above $3,000,000,000 DARZALEX continues to set the standard in multiple myeloma with another quarter of over 20% growth. In fact, just last week, we expanded our DARZALEX indication in Europe with the approval of a DARZALEX based quadruplet regimen for patients with newly diagnosed maternal myeloma regardless of transplant eligibility. It is further proof of the impact of this medicine, which together with Carvicti, Talve, and TegVyle is changing the conversation from treating to progression to treating to cure. Other significant oncology portfolio advancements in Q1 included Phase III data presented at ELCC last month showing Ribrevant plus Lascludes extended overall survival by more than one year versus the current standard of care in first line EGFR mutated lung cancer. And last week, the European Commission approved sub cutaneous ribavant in combination with Las Cruze for the treatment of EGFR mutated non small cell lung cancer.

This was an important milestone for patients as sub cutaneous ribavant reduces administration time from hours to minutes. Our aspiration is for Ribrovant plus Lascludes to become the new standard of care for these patients and you can see our progress in Q1. In immunology, we're seeing the impact of Tremfya's entry into inflammatory bowel disease with our launch in ulcerative colitis helping accelerate operational sales growth to 20. And with our recent FDA approval in Crohn's disease, I'm more confident than ever that this blockbuster drug will become the gold standard for IBD patients and a $10,000,000,000 plus product. Turning to MedTech, in Q1, we delivered 4.1% operational sales growth with strong performance in our recently acquired cardiovascular businesses, Abiomed and Shockwave as well as in Surgical Vision and wound closure.

In addition to their contribution to MedTech growth, Abbiomed and Shockwave continued to meet deal model expectations and both announced important portfolio milestones this quarter. These included updates to the American College of Cardiology and American Heart Association guidelines for our Impella heart pump, which based on evidence from the DANGER shock trial was upgraded from Class 2B to Class 2A. And in Shockwave, the team launched the first of its kind Javelin peripheral IVL catheter for the treatment of difficult to cross lesions in peripheral artery disease. In electrophysiology, we resumed US body pulse cases and to date we have completed more than five thousand five hundred cases globally. Turning to surgery, we recently announced we have started OTAVA clinical trials with a procedure that supports submission for U.

S. FDA de novo in general surgery with an indication for multiple upper abdomen procedures. This is an important milestone as we continue to strengthen our presence in robotic surgery. Beyond our existing portfolio and pipeline, we also fortified our leadership as an innovation powerhouse with two major announcements. In March, we announced our commitment to invest more than $55,000,000,000 in The U.

S. Over the next four years in manufacturing, R and D and technology. This represents a 25% increase in investment compared to the previous four years. It builds upon the company's already elevated commitment to The U. S.

Economy while expanding our capacity to manufacture next generation medicine and devices for patients in America and around the world. The investment includes four planned new manufacturing facilities, the first of which broke ground last month in North Carolina. And at the April, we announced the completion of our acquisition of Intra Cellular Therapies, which extends Johnson and Johnson's industry leading portfolio in central nervous system disorders. With the addition of CAPLYTA, we have expanded our lineup of therapies with at least $5,000,000,000 plus potential in peak year sales, further solidifying sales growth above analyst expectations now through the rest of the decade. Turning to the TALK bankruptcy ruling.

As we shared a few weeks ago, we will return to the tort system where we expect continual success in litigating these meritless claims. In terms of next steps, we will immediately pursue our motion spending in the multi district litigation to exclude plaintiffs' experts known as the Daubert Challenge. And finally, as announced this morning, we increased our dividend for the sixty third consecutive year, which we know is important to our shareholders. We had a strong start to 2025, and I'm looking forward to sharing many more successes throughout the year, recognizing that there have been many important milestones and data readouts in the quarter, I will now pass the call to John Reed for an innovative medicine R and D update.

Thank you, Joaquin. I'm excited to share a few highlights from our industry leading innovative medicine pipeline that occurred throughout the quarter. With the successful acquisition of Intracellular, I want to focus on CAPLYTA, a remarkable medicine with balanced pharmacology that delivers robust efficacy combined with a favorable tolerability profile for neuropsychiatric disorders. CAPLYTA is already approved for the treatment of schizophrenia and is the only medicine approved for the treatment of depression in both bipolar one and two as either monotherapy or adjunctive therapy. On this slide, we're sharing data for major depressive disorder showing very impressive and consistent improvements in the standard depression scoring metric, MADRS, in both phase three studies that served as the basis for submission of the supplemental new drug application to the FDA.

We anticipate approval of CAPLYTA later this year as an adjunctive treatment for major depressive disorder, representing the largest of the indications for novel antidepressant drugs today. Turning to oncology. We are so excited about our recent overall survival data for Ribrovant plus last clues in first line non small cell lung cancer harboring EGF receptor gene mutations. Non small cell lung cancer is the most prevalent type of lung cancer, making up about eighty five percent of lung cancer diagnoses. Sadly, less than twenty percent of people diagnosed with this form of the disease are alive after five years, and only a fraction live long enough to try a second treatment.

That's why it is so important to use the best treatment first. In a head to head study against today's standard of care, our Riborvant plus Lascluse regimen improved overall survival by more than a year with the Kaplan Meier survival curves continuing to separate at thirty seven point eight months median follow-up. With Riborvant's triple mechanism of action, we're looking to reset the standard five year survival expectations in a never before seen way. In simplest terms, we're giving patients more hope that they may live to celebrate another birthday, anniversary, or other important family event. A truly practice changing achievement.

Now moving on to immunology. I draw your attention to the recent FDA approval of Tremfya in Crohn's disease, our fourth indication for Tremfya. Tremfya is currently the only I l twenty three inhibitor with the flexibility of subcutaneous administration for both induction and maintenance dosing for the treatment of Crohn's disease, which means patients can start their treatment by self administering with results as rapid and robust as receiving the IV in a clinic or doctor's office. Additionally, in a recent head to head study in adult patients with moderately to severely active Crohn's disease, Tremfya demonstrated superiority versus Stelara in all pooled endoscopic endpoints. As the only dual acting IL-twenty three inhibitor, Tremfya neutralizes IL-twenty three while also binding to c d 64 in immune cells that produce I l 23, thus localizing TREMFYA right at the source of inflammation.

Tremfya continues to offer an exceptional solution for patients struggling with inflammatory bowel disease. Lastly, highlighting some of our latest data for our investigational oral IL twenty three pathway inhibitor icotrokinra, we are aiming to redefine the standard of care for people living with plaque psoriasis. Icotrokinra is the first and only targeted oral peptide that selectively blocks the I l 23 receptor. In two placebo controlled phase three studies, icotrokinra demonstrated impressive complete skin clearance and a favorable safety profile in a once daily pill. Our phase three data demonstrated that nearly half of adult patients and three quarters of adolescents with moderate to severe plaque psoriasis treated with icotrokinra achieved completely clear skin by week twenty four.

We also reported that icotrokinra achieved the prespecified endpoints in additional phase three psoriasis studies comparing our molecule head to head with the most commonly prescribed TYK2 inhibitor. Those data will be shared at an upcoming medical congress. Looking forward, we are initiating the first ever head to head study seeking to demonstrate the superiority of a pill, icotrokinra, compared to an injectable biologic, Stellara, in moderate to severe plaque psoriasis, representing an important step forward in psoriasis research. As a reminder, we intend to file icotrokinra for approval later this year. Finally, beyond psoriasis, we recently announced positive top line results from Anthem UC, our phase two b study of icotrokinra in adults with moderate to severe ulcerative colitis.

That study showed that icotrokinra achieved impressive clinical remission rates combined with a favorable safety profile, again, dosed as a once daily pill. With all this progress, you can understand why we continue to be excited about the potential of icotrokinra to transform the treatment paradigm for patients battling with autoimmune diseases. Overall, across all our therapeutic areas, we are absolutely thrilled with the progress that our pipeline has made in the first quarter of this year, and we are eager to report on other significant milestones scheduled for the remainder of 2025. And now I will turn the call over to Jess.

Thank you, John. Moving to our financial results. Unless otherwise stated, the percentages quoted represent operational results and therefore exclude the impact of currency translation. Starting with Q1 twenty twenty five sales results. Worldwide sales were $21,900,000,000 for the quarter.

Sales increased 4.2% despite an approximate four seventy basis point headwind from Stellara. Growth in The U. S. Was five point nine percent and two point one percent outside of The U. S.

Worldwide growth was positively impacted by 90 basis points due to acquisition and divestitures. Turning now to earnings. For the quarter, net earnings were $11,000,000,000 and diluted earnings per share was $4.54 versus diluted earnings per share of $1.34 a year ago, primarily driven by the reversal of $7,000,000,000 related to the talc settlement proposal. Excluding after tax intangible asset amortization expense and special items for both periods, adjusted net earnings for the quarter were $6,700,000,000 and adjusted diluted earnings per share was $2.77 representing increases of 1.92.2%, respectively, compared to the first quarter of twenty twenty four. We are proud to deliver bottom line growth despite the loss of exclusivity of Solara and the impact of Part D redesign.

I will now comment on business sales performance in the quarter. Beginning with Innovative Medicine. Worldwide sales of $13,900,000,000 increased 4.2% despite approximate eight ten basis point headwind from Stellara. Growth in The U. S.

Was six point three percent and one point five percent outside of The U. S. Starting with Oncology. DARZALEX growth was 22.5%, primarily driven by continued share gains of approximately three points across all lines of therapy and approximately five points in the frontline setting as well as market growth. PERVICTI achieved sales of $369,000,000 and growth of over 100%, driven by share gains and capacity expansion.

This reflects sequential growth of 10.5% as we continue to expand outside of The U. S. Tekveli and Talve growth was 1550.2%, respectively, reflecting strong launches in the relapsedrefractory setting. Patient demand remained strong despite continued adoption of longer dosing intervals. ERLEADA continued to deliver strong growth of 14.6% despite the impact of Part D redesign, primarily driven by share gains and market growth.

Ribrovant plus Lascluse continued its strong launch trajectory with sales of $141,000,000 and growth over 100%. Within immunology, Tremfya delivered growth of 20.1% despite the impact of Part D redesign, driven by share gains and market growth across all indications, including our newly launched indication in ulcerative colitis. ZOLARA declined 32.3%, driven by the impact of of biosimilar competition and Part D redesign. As a reminder, REMICADE and SYMPHONY distribution rights in Europe were returned in Q4. This positively impacted results in the quarter and is anticipated to continue for the remainder of the year.

Remicade sales also include a onetime patient mix benefit in The U. S. In neuroscience, growth of 42.9% was driven by increased physician and patient demand. Finally, other assets that were impacted by Part D redesign include Envigo long acting injectables, which declined thirteen point five percent pulmonary hypertension, which declined one point two percent and was partially offset by market growth and share gains and Xarelto, which increased by 33% and also included a onetime patient mix benefit. I'll now turn your attention to medtech.

Worldwide sales of $8,000,000,000 increased 4.1% with growth of 5.1% in The U. S. And 3% outside of The U. S. Acquisitions and divestitures had a net positive impact of two eighty basis points on worldwide growth, four twenty basis points in The U.

S. And 120 basis points outside of The U. S. MedTech performance was driven by commercial execution and strength of new products, partially offset by several onetime events disproportionately impacting orthopedics, in addition to continued competitive PFA pressures in electrophysiology and headwinds in China. Results were negatively impacted by approximately two ten basis points worldwide, two forty in The U.

S. And 180 outside of The U. S. Due to these onetime events. In cardiovascular, electrophysiology growth was roughly flat versus prior year driven by lapping of prior year inventory dynamics in Asia, impacting worldwide results by roughly three ten basis points and competitive PFA ablation catheter pressure.

This was mostly offset by global procedure growth, new product uptake and commercial execution. Abiomed delivered growth of 14% driven by strong growth in all regions and continued adoption of Impella five point five and Impella CP technology. Cardiovascular results also included $258,000,000 associated with the acquisition of Shockwave. As a reminder, we will lap the acquisition benefit at the May. Envision, contact lenses and other grew 2.7% driven by continued strategic price actions and strong performance in the AccuView Oasis one day family of products.

Surgical vision growth of 6.2% was driven by our recent innovations, Technis Odyssey, Pure C, and iHands, as well as commercial execution, partially offset by competitive pressures in The U. S. Surgery grew 1.1% with divestitures negatively impacting results by approximately 180 basis points. Performance was driven primarily by commercial execution and the continued strength and adoption of new products across wound closure and biosurgery. Growth was partially offset by competitive pressures in energy and endocutters as well as the negative impact of China VBP.

Given the disproportionate impact of the onetime events to orthopedics, I'd like to draw your attention to this additional slide. Orthopedics declined 3.1%, primarily driven by the lapping of a one time revenue recognition timing change related to certain products across all platforms in The US. Fewer selling days and revenue disruption from the previously announced orthopedics transformation. These onetime events negatively impacted worldwide orthopedics growth by approximately four eighty basis points, six fifty basis points in The U. S.

And two ten basis points outside of The U. S. This was partially offset by success of new product launches and commercial execution. Now turning to our consolidated statement of earnings for the first quarter of twenty twenty five. I'd like to highlight a few noteworthy items that have changed compared to the same quarter of last year.

Cost of products sold deleveraged by three twenty basis points, driven by unfavorable transactional currency and product mix, primarily due to the decline of Stellara in Innovative Medicine as well as the fair value step up in amortization associated with the Shockwave acquisition in MedTech. Selling, marketing and administrative expenses improved 130 basis points driven by operating spend management and phasing of investments, primarily in innovative medicine. Research and development expenses leveraged by 190 basis points, primarily driven by portfolio progression towards commercialization and phasing of investments in Innovative Medicine, partially offset by investments associated with the recent acquisitions of Shockwave and VWave in medtech. Interest income and expense was a net income of $128,000,000 as compared to $2.00 $9,000,000 in the first quarter of twenty twenty four, primarily driven by higher interest rates paid on higher average debt balances. Other income and expense was a net income of $7,300,000,000 compared to an expense of $2,400,000,000 in the prior year, driven by the $7,000,000,000 talc reserve reversal in the first quarter of twenty twenty five and the $2,700,000,000 talc settlement proposal recorded during the first quarter of twenty twenty four.

Regarding taxes in the quarter, our effective tax rate was 19.3% versus 12.4% in the same period last year, primarily driven by the tax effect of the reversal of the talc settlement accrual. Excluding special items, the effective tax rate was 16.3% versus 16.5% in the same period last year. I encourage you to review our upcoming first quarter ten Q filing for additional details on specific tax related matters. Lastly, I'll direct your attention to the box section of the slide where we have also provided the company's income before tax, net earnings and earnings per share adjusted to exclude the impact of intangible amortization expense and special items. Now let's look at adjusted income before tax by segment for the quarter.

New this quarter and to continue our efforts of increased financial transparency, you will find GAAP to non GAAP reconciliations by segment in the supplemental schedules of our press release. Innovative medicine margin declined from 42.9% to 42.5%, primarily driven by unfavorable transactional currency and product mix and cost of products sold and Part D redesign, partially offset by operating leverage. MedTech margin declined from 26.4% to 25.9%, primarily driven by R and D and selling, marketing and administrative investments associated with the recent acquisition of Shockwave and VWave. As a result, adjusted income before tax for the enterprise as a percentage of sales decreased from 36.8% to 36.6%. This concludes the sales and earnings portion of the call, and I will now turn the call over to Joe.

you for joining us today. Thanks, Jessica, not just for the transition now, but also for how well you have led the Investor Relations function in the past few years. The investment community will miss you, but we look forward to seeing you in the lead finance role for Innovative Medicine. Our first quarter results demonstrate the strength and reliability of Johnson and Johnson's diversified business model. Innovative Medicine achieved robust growth in the face of Stellara biosimilar entrants, and we advanced our pipeline, attaining significant clinical and regulatory milestones.

In medtech, as indicated in January, we anticipated pockets of challenge early on and are planning for higher second half growth in those areas of our business. The team is focused on commercial execution and accelerating the recently launched products to deliver medtech's commitments that are included in the company's full year guidance. The recent acquisitions of Abiomed and Shockwave continue to expand our presence in higher growth markets. In addition, we continue to take steps to improve MedTech's future margin profile, implementing a restructuring program designed to simplify and focus the operations of our surgery business, similar to what we launched in orthopedics in 2023. Focusing on portfolio renewal, we plan to exit certain non strategic product lines globally and optimize select sites across the network.

We anticipate some modest short term revenue disruption in surgery of approximately $250,000,000 in total over the next two years, but these actions will improve our ability to accelerate growth and enhance profitability. The program is expected to be completed in 2027 with cost estimated at approximately $900,000,000. Let's now turn to cash and capital allocation. We are pleased with free cash flow generation in the quarter of approximately $3,400,000,000. We ended the first quarter with $38,800,000,000 of cash and marketable securities and $52,300,000,000 of debt for a net debt position of $13,500,000,000 It is important to note that cash and net debt were favorably impacted by approximately $14,000,000,000 of cash held in anticipation of the Intercellular acquisition, which closed on April 2.

Taking this into consideration, net debt would have been approximately $27,500,000,000. Investment and innovation remains the highest priority in our capital deployment. And during the first quarter, we invested more than $3,000,000,000 in research and development, approximately 15% of sales. We also remain committed to returning capital directly to shareholders. We recognize the value investors place on our dividend, and we were pleased to announce today that our board of directors authorized a 4.8% increase, marking our sixty third consecutive year of dividend increases.

The Intercellular Therapies acquisition bolsters our neuroscience portfolio, and we maintain a disciplined approach to inorganic growth, focusing on acquisitions and partnerships that align strategically and offer value creation. As noted in our talc investor call and following up on some of Joaquin's earlier comments, we reversed $7,000,000,000 of the reserve previously held for the bankruptcy plan. This litigation has not and we foresee will not impact our ability to execute upon our capital allocation priorities to appropriately manage our business. Let's now discuss our full year guidance for 2025. We are increasing our operational sales guidance for the full year by $700,000,000 to reflect the addition of CAPLYTA following the completion of the Intercellular acquisition.

Therefore, we now expect operational sales growth for the full year to be in the range of 3.3% to 4.3% with a midpoint of $92,000,000,000 or 3.8%. Excluding the impact from acquisitions and divestitures, we are maintaining our adjusted operational sales growth to the range of 2% to 3% compared to 2024. As you know, we don't speculate on future currency movements. And last quarter, we utilized the euro spot rate relative to the US dollar of 1.04. Last week, the euro spot rate relative to the US dollar was 1.11.

We estimate an incremental positive foreign currency impact of $1,100,000,000 versus previous guidance, resulting in a full year headwind of $600,000,000 As such, we now expect reported sales growth between 2.6% to 3.6% with a midpoint of $91,400,000,000 or 3.1%. Turning to other notable items on the P and L. We are maintaining our guide of operating margin improvement by 300 basis points versus twenty twenty four. This improvement takes into consideration the dilution from the intracellular transaction as well as what we know today about the impact of tariffs on our business. We now project net interest expense between $100,000,000 and $200,000,000 primarily driven by financing costs associated with the Intercellular acquisition.

Other income is anticipated to be in the range of $1,000,000,000 to $1,200,000,000 a slight increase versus previous guidance. Despite $0.25 dilution from the Intercellular acquisition and including the impact of tariffs based on what is in place today, we are pleased to be able to maintain our adjusted reported earnings per share guidance of 6.2% at the midpoint for a range of $10.50 to $10.70, partially aided by the reduced FX impact. I'll now provide some qualitative considerations on phasing for your models. We continue to expect both Innovative Medicine and MedTech operational sales growth to be higher in the second half of the year versus the first half. Regarding innovative medicine, we maintain the assumption that the impact of Stellara biosimilar competition will accelerate throughout the year, similar to Humira's erosion curve, which is still our proxy with the additive impact of Part d redesign.

The impact of Part d redesign on affected products as a percent of sales will be consistently applied throughout the year, aligned with how we traditionally account for similar discount and rebate programs. Naturally, we expect a greater benefit from our newly launched products as the year progresses. Regarding med tech, we expect normalized procedure volume and seasonality. And of course, we anniversary the Shockwave acquisition at the May. We anticipate our newly launched products to build throughout the year with the relaunch of Varipulse in The US, the introductions of dual energy STSF in The EU, Velis UniKey, Velis Spine, and Technis Odyssey.

Lastly, this slide highlights the onetime prior year p and l items that should be taken into quarterly consideration for your models. Beyond our financial commitments and what Joaquin and John mentioned, we are excited for the pipeline progress plan for the remainder of 2025. In innovative medicine, this includes expected approvals in nipocalimab for generalized myasthenia gravis, subcutaneous Ribrovant for non small cell lung cancer in The US, Tremfya Subcutaneous Induction for ulcerative colitis, and CAPLYTA for adjunctive major depressive disorder. We continue our rolling submission of TAR 200 in non muscle invasive bladder cancer and anticipate filing icotrokinje in psoriasis. Plan data readouts for Ribrovant in head and neck cancer and icotrokinje in ulcerative colitis, as well as head to head data versus CTIC two in psoriasis.

In med tech, we continue to make progress with clinical trials for our Ottava robotic surgical system and across our cardiovascular portfolio, including heart recovery with Impella ECP submission and circulatory restoration with Javelin and Shockwave E8 launches. This progress will bode well for financial performance for the balance of this decade. In fact, building on John's earlier discussion on our innovative medicine pipeline and what I just outlined, I'd like to revisit and update a slide that we shared at our enterprise business review in late twenty twenty three. In that slide, you may recall we highlighted key assets in our portfolio that we expected to drive long term growth and projected higher revenue than street estimates. We've been pleased to see some estimates have been raised since the 2023 enterprise business review, and now I'd like to walk you through some of our current thinking on our pipeline potential to show where we see even more upside.

Based on current 2027 Street estimates, our projections are at least two times higher for Ribrovant plus Last Clues and at least 50% higher for SPRAVATO. One asset that we didn't highlight in this look back in 2023 was Tremfya. However, given recent regulatory approvals for inflammatory bowel disease, we now see sales for Trimfya at least 25% higher than current street estimates. When looking ahead to 2028, we anticipate sales for our intravascular drug releasing system, previously referred to as TARUS, to be at least three times higher than current street estimates, and new to the chart, icotrokinje, our targeted oral peptide, to be at least two times higher. To be balanced, analyst estimates are still a bit more optimistic than our own estimates on nipocalimab in 2027.

However, we do anticipate closing that gap after launch. We have even stronger conviction today in our growth opportunities than at the enterprise business review as we've reached new milestones with each of these medicines. And importantly, we expect all these assets to achieve peak year sales beyond 2028 with further potential upside to street estimates in the outer years. Even after considering risk adjustments for unapproved products that you may apply, hopefully, you'll also conclude there is additional value to your outlooks. In summary, it was a solid start to the year.

Johnson and Johnson's diversified business model uniquely positions us to tackle the headwinds in 2025, deliver on our financial commitments, and advance our pipeline to create long term sustainable value for shareholders. Thank you. And with that, we are happy to take your questions. Kevin, will you please provide instructions for those seeking to participate in the q and a?

Certainly. We'll now be conducting a question and answer session. Ladies and gentlemen, if you'd like to ask a question at this time, please press star then one on your telephone keypad. If you'd like to withdraw your question, press then 2. Our first question today is coming from Larry Biegelsen from Wells Fargo.

Good morning. Thanks for taking the question and congrats on a nice quarter. Joe, you talked about $400,000,000 in tariffs in the 2025 guidance or about $0.14 by our math. What is that on an annualized basis? And how are you thinking about being able to mitigate that over time?

Can you pass it along to customers, or or can you offset it by moving, production? Thanks for taking the question.

Yeah. Thanks, Larry. Good to hear from you. So what's included in the $400,000,000? And, that is primarily med tech tariffs at this point.

It's based on the programs that have been announced and the timing that correlates with those programs. So that would be inclusive of Mexico and Canadian import tariffs that are not excluded out of USMCA. It'll include to a very small degree some of the steel and aluminum tariffs that impact some of our products. It includes the China tariffs, as well as the China retaliatory tariff. And that is probably the most substantial out of all the tariffs in terms of that $400,000,000.

And and so just to to maybe clarify for everybody, that that is products of US origin being shipped into China, and that's probably the most penalizing factor. That $400,000,000, I don't wanna be cavalier about that. It's obviously the the program has been phased in as a partial year. And then you have mostly this being captured as cost of goods, it's gonna sit on the balance sheet in inventory and be, relieved to the p and l in future periods. So that's how that's how we're thinking of it.

In terms of mitigation strategies, I think you know across our entire business, we're very limited in terms of price leverage, whether it be on the med tech side. There's, contractual agreements already in place and certainly very much precluded on the pharmaceutical side, on current products that exist in terms of taking price increase. And I know Joaquin has a few thoughts regarding tariffs and maybe other mitigation factors and the supply nature of, health care.

Thank you, Joe, and thank you, Larry, for the question. Thinking about tariffs and thinking specifically about pharmaceutical tariffs, there's a reason, Larry, why pharmaceutical tariffs are zero. It's because tariffs can create disruptions in the supply chain leading to shortages. If what you want is to build manufacturing capacity in The U. S.

Both in medtech and in pharmaceuticals, the most effective answer is not tariffs, but tax policy. As a matter of fact, since President Trump's twenty seventeen tax reform, the investment in manufacturing both in medtech and in pharmaceuticals has significantly increased. And when you think about our recent announcement of investing $55,000,000,000 over the next four years at the completion of this investment plan. Essentially, all our advanced medicines that are used in The U. S.

Will be manufactured in The U. S. So tax policy is a very effective tool to be able to build manufacturing capacity here in The US both for med tech and pharmaceuticals.

Hey, Larry. I just wanna follow-up too. You did ask about a full year impact. And I I will say I purposely ignored question only because it would be way too speculative at this point. As we know, these tariffs are very fluid, and the responsible action for us now is to quantify what we see the impact in 2026 and then see what happens with respect to, does it, lend itself to negotiations with other countries and what's actually in place as we get into the the later part of 2025.

Thank you. Next question today is coming from Chris Schott from JPMorgan Chase and Company. Your line is now live.

Great. Thanks so much. Just had a question on gross margins in the quarter. It seems like these came in well below recent trends. I'm just trying get a better understanding of the drivers there and just the outlook going forward as we consider mix, tariffs, etcetera, on the gross margin line?

Hey, Chris. This is Joe. Thanks for the question. So I'll say it's, there's a two part answer to this one. So specifically, in the quarter, when looking at first quarter of twenty twenty four, we obviously had the impact of, Stellara, which was a much higher gross margin product than our average, product in our portfolio.

You had Part d, which is exclusively price, which is eroding margin. And then you had some, I would say, transactional currency headwinds, one, a favorable impact last year or in 2023 funneling into 2024,

some unfavorability from last year's, currency action. I would expect moving forward, based on some of the plans that we have, you could expect that that 300 basis points to probably improve by a third to 50%, and that would be inclusive of the tariffs that I just mentioned in Larry's question. Question. The other thing I would say is, I know you you guys do a great job, but I think analysts were maybe a little bit optimistic with respect to their outlook for gross profit, given that we had Stellara and Part D certainly communicated in the past. I believe the consensus was taking gross margins up year over year, and that one was probably a little bit of a miss.

So we probably could've done a better job explaining it.

Thank you. Next question is coming from Assad Hayder from Goldman Sachs. Your line is now live.

Thanks for taking the question. Just going back to the Stellara biosimilar version and the acceleration of the trajectory that we're gonna see over the course of the year, Are you able to provide any quantitative framing on your views as it relates to the extent to which you think this, erosion gets smoothed out by the transition to other brands like Trampfire and other products? Thank you.

Well, good morning. Thanks so much for the question. It it's Jennifer. What we saw with Stellara in the first quarter was definitely in line with our expectations for the product for the year, and we continue to guide to the HUMIRA two year erosion curve once there were multiple biosimilars as really the best model there and make sure that we're also including the additional impact of Part D redesign. If I could one additional point around, Stellara, if we take a look at the business overall, it was highlighted that we had 4.2% growth across Innovative Medicine.

Johnson & Johnson (JNJ) Q1 2025 Earnings Call Transcript

Company Participants